



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2369010 C 2010/06/08

(11)(21) **2 369 010**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2000/04/17
(87) Date publication PCT/PCT Publication Date: 2000/10/26
(45) Date de délivrance/Issue Date: 2010/06/08
(85) Entrée phase nationale/National Entry: 2001/09/25
(86) N° demande PCT/PCT Application No.: US 2000/010430
(87) N° publication PCT/PCT Publication No.: 2000/063420
(30) Priorité/Priority: 1999/04/16 (US60/129,730)

(51) Cl.Int./Int.Cl. *C12Q 1/48* (2006.01),
C12Q 1/28 (2006.01)
(72) Inventeurs/Inventors:
HAN, QUINGHONG, US;
TANG, LI, US;
XU, MINGXU, US;
TAN, YUYING, US;
YAGI, SHIGEO, US
(73) Propriétaire/Owner:
ANTICANCER, INC., US
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : METHODE DE DETERMINATION DU TAUX DE CONCENTRATION D'ACIDE FOLIQUE DANS UN
ECHANTILLON BIOLOGIQUE
(54) Title: METHOD FOR DETERMINING LEVEL OF FOLATE IN A BIOLOGICAL SAMPLE

(57) **Abrégé/Abstract:**

A method to assess the level of folate in a biological sample comprises: providing said sample with glycine N-methyltransferase (GMT) and with an excess of S-adenosyl methionine (SAM) and of glycine; providing a control which contains no folate with said GMT and excess SAM and glycine in comparable amounts to those provided to the sample; and comparing the concentration of at least one product formed in the sample with the concentrations of said product formed in the control, whereby the difference in levels of said product in the sample as compared to the control is directly proportional to the level of folate in the sample.



BIOLOGICAL FLUID ASSAY METHODS**ABSTRACT**

A method to assess the level of folate in a biological sample comprises: providing said sample with glycine N-methyltransferase (GMT) and with an excess of S-adenosyl methionine (SAM) and of glycine; providing a control which contains no folate with said GMT and excess SAM and glycine in comparable amounts to those provided to the sample; and comparing the concentration of at least one product formed in the sample with the concentrations of said product formed in the control, whereby the difference in levels of said product in the sample as compared to the control is directly proportional to the level of folate in the sample.

METHOD FOR DETERMINING LEVEL OF FOLATE IN A BIOLOGICAL SAMPLE

This application is the national phase of PCT application PCT/US00/10430 filed 17 April 2000 which claims priority to U.S. 60/129,730 filed 16 April 1999.

5 Technical Field

The invention relates to diagnostic methods for conditions which are characterized by abnormal levels of certain metabolites, in particular, folates, and to simplified methods of detection. The improved methods of the invention provide rapid and accurate assessment of the concentrations of folate and other analytes.

10 Background Art

Folates are critical co-factors in methyl transfer reactions. Abnormalities of folate levels in biological fluids such as blood and plasma are indicative of conditions that are characterized by inappropriate or inadequate transfer of methyl groups. Thus, it is important to be able to provide an accurate measure of folate levels in such fluids and to
15 compare them to those expected in normal individuals. Low folate concentrations are associated with megaloblastic anemia and reduced DNA synthesis, as well as cardiovascular disease. Birth defects may also result.

Folate can be measured efficiently using the methods of the invention. The invention also provides an improved method to detect H_2O_2 in the presence of peroxidase

20 Disclosure of the Invention

The invention method for determining levels of folate in biological fluids takes advantage of the ability of folate to inhibit the methyl transfer reaction whereby glycine is converted to sarcosine. The enzyme which carries out this conversion, glycine N-methyltransferase (GMT) can be isolated from liver or pancreas. In the assay systems of the invention,
25 glycine and S-adenosyl methionine (SAM) are the reactants and sarcosine and S-adenosyl homocysteine (SAH) are the products. The effectiveness of GMT in converting these reactants is dependent on folate concentration *in vivo*.

The folate in the sample can be converted to a form (to the extent it does already exist in said form) whereby it inhibits the ability of GMT to form the foregoing products. The folate in the sample is first converted to folypoly glutamate (FPG) which is an inhibitor of the GMT. Yeo, E-J, *et al.*, *J. Biol. Chem.* (1999) 274:37556-37564. Under these

5 conditions, the greater the amount of folate in the sample, the less products formed.

In the invention method, the levels of product are typically measured. As the levels of reactants are provided in excess, although it is theoretically possible to measure the diminution in reactants, this is less desirable as it is, of course, more difficult to detect small differences in large concentrations than to measure a difference from zero.

10 However, it is not impossible, and such measurements are within the scope of the invention as well.

Either the levels of SAH or of sarcosine can be measured or both. A variety of methods is available in each case. Preferred embodiments for the measurement of SAH, however, include its conversion to homocysteine and subsequent lysis of homocysteine to obtain

15 readily detectable products as further described below. In the case of sarcosine, a convenient method is the use of a specific oxidase which, in the presence of this amino acid, generates hydrogen peroxide which can also be readily detected by a variety of methods known in the art, preferred embodiments of which are illustrated below. Thus, in one aspect, the invention is directed to:

20 A method to assess the level of folate in a biological fluid sample which method comprises

providing said sample with glycine N-methyltransferase (GMT) and with an excess of S-adenosyl methionine (SAM) and of glycine;

25 providing a control which contains no folate with said GMT and excess SAM and glycine in comparable amounts to those provided to the sample; and

comparing the concentration of at least one product formed in the sample with the concentrations of said product formed in the control,

whereby the difference in levels of said product in the sample as compared to the control is directly proportional to the level of folate in the sample.

30 In the foregoing method, either sarcosine or SAH levels may be measured. The concentrations of products will be diminished in the sample as compared to the control.

Pretreatment of the sample with an enzyme which converts folate to an inhibitor of GMT, FPG, set forth above, is desirable. This enzyme, folypoly glutamate synthetase (FPGS) is readily available in the art.

In another aspect, the invention is directed to a particularly convenient method for the
5 endpoint of sarcosine measurement. It has been found that a particularly convenient method to measure hydrogen peroxide in analytical samples, including biological fluids, is to treat the sample containing the peroxide with both peroxidase and a dialkyl phenylene diamine. The resultant is a colored compound which can be measured spectrophotometrically. As will be evident, since a number of protocols are available
10 which result in the generation of hydrogen peroxide, for example the treatment of substrates with their pertinent corresponding and specific oxidases, the combination of peroxidase and dialkyl phenylene diamines has a broad range of utility.

Modes of Carrying Out the Invention

The invention is directed, in one embodiment, to the measurement of folates in biological
15 fluids. Suitable biological fluids are most commonly blood, serum and plasma, although other fluids may be of interest as well, such as cerebral spinal fluid, urine, and other blood fractions. Measurement in plasma or serum is preferred.

By "folates" is meant folic acid and its salts as well as the dihydro and tetrahydro form. In order to ensure uniformity of results, it may be desirable to add a reducing agent to the
20 reaction mixtures in order to ensure that all of the folates are in the same oxidation state - *i.e.*, the tetrahydro folate (THF) form. However, it is believed that the predominant form, almost to the exclusion of the others, in biological systems is tetrahydrofolate, and in particular, 5-methyltetrahydrofolate. It is this form, specifically, in combination with glutamate which acts as an inhibitor of GMT endogenously.

25 By way of background, it is believed that the function of GMT in the liver and pancreas is to diminish undesirably high concentrations of SAM by creating a "sink" in the form of sarcosine, which has no known function. However, this enzyme is regulated by folate; when high levels of methylated THF are present, combination with glutamate occurs and the resulting compound is a powerful GMT inhibitor. The present invention takes
30 advantage of the ability of folates to inhibit GMT using this mechanism.

For use in the present invention, GMT can be isolated from pancreas or liver or theoretically could be produced recombinantly. If the enzyme is isolated from native sources, it should first be treated to disassociate it from any endogenous folate. This can be effected by treating the enzyme with an anion exchange column and effecting a separation using, for example, a gel exclusion method.

In the methods of the invention, glycine N-methyltransferase (GMT) catalyzes the reaction:



The GMT is purified from any convenient source. A method for purification of the enzyme from rat liver is described in the examples below; also described is a method to obtain the enzyme free of inhibitor by treating the isolated GMT on an anion exchange column and separating the dissociated folate by gel filtration.

To carry out the method, both control and sample are incubated with folate-free GMT after treatment with glutamic acid in the presence of the enzyme FPGS which converts any folate into an inhibitor of GMT, FPG. Either sarcosine or SAH can be measured, the amounts or concentrations of product present in the sample will be less than those of the control in a degree proportional to the concentration of folate in the sample.

Thus, the sample and the control are treated with glutamine and the synthetase FPGS to convert the folate to an inhibitor (FPG) of the GMT. In this embodiment, the sample is incubated with the glutamine and FPGS in suitable amounts prior to or concomitant with, treatment with GMT. The remainder of the assay is conducted according to the alternatives outlined below. Measurement of SAH or sarcosine provides a measure of the GMT activity which is, in turn, inversely proportional to the level of inhibitor, and thus inversely proportional to the level of folate in the sample.

Detection of SAH

In a preferred method for detection of SAH, the reaction mixtures are treated with S-adenosyl homocysteinase (SAHase) which converts SAH to homocysteine.

Homocysteine can then be measured by any method convenient in the art. However, a particularly preferred embodiment employs a recombinant homocysteinase (HCYase), preferably HYaseTM, which is especially specific for homocysteine. This enzyme is described in detail in PCT publication No. WO99/05311 published 4 February 1999.

The use of this particular HYase™ homocysteinase has the advantage of substantially and essentially eliminating any background products which might be formed from methionine or cysteine present in the sample. The products of homocysteine catalysis by this enzyme are ammonia, hydrogen sulfide, and
5 α ketobutyrate. Any of these products may be measured, but it is most convenient to measure the hydrogen sulfide by the use of an oxidizing agent in the presence of any dialkyl phenylene diamine, most conveniently the di-N-butyl embodiment, DBPDA. The complex that is formed between hydrogen sulfide and the dialkyl phenylene diamine in the presence of an oxidizing agent is both chromogenic and fluorescent, and either property
10 can be used for detection. Use of the fluorescence property appears slightly more sensitive.

Thus, in one preferred embodiment, the reaction mixture is treated with SAHase and recombinant homocysteinase HYase and with the chromogen DBPDA and an oxidizing agent such as ferric ion. Either the absorbance at about 675 nm or the fluorescence upon
15 excitation at about 665 nm and emission at 690 nm is measured.

Measurement of Sarcosine

The levels of sarcosine product can conveniently be measured by use of sarcosine-specific enzymes. A particularly preferred sarcosine-specific enzyme is sarcosine oxidase Santos, F., *et al.*, *Electrophoresis* (1995) 16:1898-1899, which generates hydrogen peroxide.
20 Dialkyl phenylene diamines are also chromogenic in the presence of hydrogen peroxide upon breakdown with peroxidase; alternatively, a colored product can be obtained using other reagents, such as 4-chloro-1-naphthol and ortho-toluidine.

Measurement of Peroxide

There are many biological reactions, especially oxidase reactions, which are specific for
25 individual substrates and which result in the production of hydrogen peroxide. Another aspect of the invention is an improved method to measure the concentration of hydrogen peroxide which method comprises adding to the sample where in the peroxide is to be measured both peroxidase, such as horseradish peroxidase, and a dialkyl phenylene diamine. A preferred compound is DBPDA. Illustrative amounts of these reagents are
30 described in the examples below.

The product of the reaction can be measured spectrophotometrically. Alternatively, a fluorescent product is formed which can be detected accordingly.

The following examples illustrate but do not limit the invention.

Preparation A

5 Purification of Rat Liver Glycine N-Methyltransferase (GMT)

The method is a modified form of that described by Ogawa, H., *J. Biol. Chem.* (1982) 257: 3447-3452; Yeo, E.J., *J. Biol. Chem.* (1992) 267: 24669-24674.

Rats were killed by decapitation and the livers quickly removed and chilled on ice. About 400 g liver was homogenized in a blender with 1.2 l. of 10 mM buffer, pH 7.2, containing
10 1 mM EDTA. After adjusting to pH 5.5 by dropwise addition of 1.0 M sodium acetate, the precipitate was removed by centrifugation at 10,000 x g for 15 min. The clear supernatant solution was recovered and adjusted to pH 7 with 2 N KOH.

The supernatant was made 1% ammonium sulfate and the mixture was allowed to stand for 30 min. with gentle stirring. After centrifugation at 10,000 g for 30 min, the
15 supernatant was recovered and treated with 8 g of ammonium sulfate per 100 ml of supernatant. After 30 min, the mixture was centrifuged as above, and the pellet was recovered, dissolved and dialyzed overnight.

The dialyzed enzyme preparation was divided into equal parts and each was put onto a column of DEAE-SepharoseTM (5 x 25 cm) equilibrated with 10mM buffer, pH 7.2,
20 containing 1 mM EDTA. The pass-through fractions were combined and ammonium sulfate added at 30 g/100 ml. After standing overnight, the pellet was collected by centrifugation and dissolved in buffer.

The enzyme solution containing 1.0 M ammonium sulfate was applied to a Phenyl Sepharose 6 FF (5 x 25 cm) column prewashed with 10 mM buffer, pH 7.2, containing 1.0
25 M ammonium sulfate. The bound GMT protein was eluted in a linear gradient of decreasing the ammonium sulfate concentration, using 10 mM buffer, pH 7.2. The peak showing the activity was collected and dialyzed overnight.

Preparation BPreparation of Apo GMT

Folate was removed from the GMT prepared as in Preparation A. The enzyme solution prepared in Preparation A was passed over an anion exchange column to dissociate the folate ligand, followed by centrifugal gel exclusion using standard methods.

Preparation CPreparation of the Inhibitor FPG

FPG was prepared from serum or from standard 5-methyltetrahydrofolate solutions by treating with recombinant human FPGS (Paresh, C., *Protein Exp & Pur* (2000) 18: 36-45). Serum or 5-methylTHF was incubated with 3 mg purified recombinant human FPGS (0.1 μ M) in the presence of 15 mM glutamic acid, 10 mM $MgCl_2$, 5 mM ATP, 20 mM KCl, 100 mM β -mercaptoethanol, 250 μ g BSA, 100 mM Tris-HCl, pH 8.7, in a total volume of 500 μ l at 37° C for 1.0 hour.

Example 1Determination of Folate by Inhibition of GMT by FPG

GMT (0.95 μ g) as prepared in Preparation A was treated to associate with FPG in a reaction mixture of standard (1-100 nM FPG) or test serum sample containing 20 mM Tris-HCl, pH 9.0 and 5 mM DTT. Various dilutions of Preparation C (FPG prepared from standard methylTHF or from serum) were included in an 800 μ l reaction mixture which was incubated for 15 min. at 25° C.

After the GMT and FPG (either standards or derived from serum) were allowed to associate, the volume was brought in each sample to 1000 μ l with 100 μ l 5 mM glycine and 100 μ l 1 mM SAM. This reaction system also included the assay mixture of 10 μ l recombinant SAHase (2.0 units/ml) and recombinant HYase (300 units/ml). It was incubated at 37° C for 30 min. During this period, any SAH product is converted to homocysteine and then to hydrogen sulfide, ammonia and pyruvate.

After the 30 min. incubation, 50 μ l 40 mM DBPA and 40 mM $K_3Fe(CN)_6$ were added and the reaction mixture was incubated at 37° C for 10 min. and read at 675 nm.

Example 2Alternate Assessment Method

- A. Assessment of folate in serum was carried out as set forth in Example 1 except that instead of including SAHase and HCYase in the reaction mixture, the reaction system
5 contains 10 μ l sarcosine oxidase (SOX) (4 mg/ml) peroxidase (2 mg/ml) and 10 μ l of 4-chloro-1-naphthol (2% W/V in diethylene glycol) and 20 μ l of o-toluidine (saturated solution in 7% acetic acid). The incubation was again at 37°C and the optical density was read.
- B. The assay of paragraph A was carried out except that no 4-chloro-1-naphthol or o-
10 toluidine were added to the reaction mixture. Instead, 5 mM DBPDA was included, and the optical density read at 558 nm at the end of the 30 min. incubation.

Claims

1. A method to assess the level of folate in a biological fluid test sample which method comprises,

adding to said test sample that is pretreated or concurrently treated with folypoly
5 glutamate synthetase (FPGS), purified apo glycine N-methyl transferase lacking folate and
an excess of S-adenosyl methionine (SAM) and of glycine;

to a control sample that contains no folate, adding apo GMT and excess SAM and
glycine in comparable amounts to those added to the test sample; and

measuring the concentration of sarcosine or S-adenosyl homocysteine (SAH) in the
10 test sample and in the control sample;

comparing the concentration of at least one of sarcosine or SAH formed in the
sample with the concentrations of sarcosine or SAH formed in the control,

whereby the amount by which the concentration of said sarcosine or SAH in the test
sample is less than the concentration in the control sample is directly proportional to the
15 level of folate in the test sample.

2. The method of claim 1 wherein said SAH is measured by a method which
comprises treating the test sample and control sample with SAHase to convert SAH to
homocysteine and with homocysteinase (HCYase) to produce α -ketoglutarate (α kg) and H_2S
and measuring the concentration of at least one of said α kg and H_2S .

20 3. The method of claim 2 wherein H_2S is measured.

4. The method of claim 3 wherein said measuring comprises treating the test
sample and control sample with a dialkyl phenylenediamine and an oxidizing agent.

5. The method of claim 4 wherein the dialkyl phenylene diamine is di-N-butyl
phenylenediamine (DBPDA) and the oxidizing agent is ferric ion.

25 6. The method of claim 1 wherein said sarcosine is measured by treating said
test sample and control sample with sarcosine oxidase and measuring the level of hydrogen
peroxide formed by reaction of sarcosine with sarcosine oxidase.

7. The method of claim 6 wherein said measuring comprises treating with peroxidase.

8. The method of claim 7 wherein said measuring further comprises providing the sample with a dialkyl phenylene diamine.

5 9. The method of claim 8 wherein the dialkyl phenylene diamine is DBPDA.

10. The method of claim 7 wherein said measuring further comprises providing said test sample and control sample with 4-chloro-1-naphthol and o-toluidine.

10 11. A method to detect the presence or amount of hydrogen peroxide in a sample, which method comprises contacting said sample with reagents consisting essentially of a peroxidase and a dialkyl phenylenediamine, whereby a color is produced in the sample in the presence of hydrogen peroxide, and

detecting the presence or amount of said color, wherein the presence or amount of said color indicates the presence or amount of hydrogen peroxide.

15 12. The method of claim 11 wherein said dialkyl phenylenediamine is di-N-butyl phenylenediamine (DBPDA).

13. The method of claim 11 or 12 wherein said peroxidase is horseradish peroxidase.

14. The method of any one of claims 11-13 wherein said detecting is performed spectrophotometrically.

20 15. The method of any one of claims 11-13 wherein said detecting is performed fluorometrically.